Alamar Biosciences IPO
Alamar Biosciences develops ultrasensitive protein detection technologies for biomarker discovery and clinical diagnostics. The company's NULISA platform enables researchers to detect and quantify thousands of proteins simultaneously, positioning it as a key player in the growing precision medicine market.
Key Facts
| Industry | Biotechnology |
| Founded | 2017 |
| Headquarters | Fremont, CA |
| Funding | Raised $191M in IPO (upsized offering priced at $17 per share at the high end of range); shares began trading on Nasdaq under ticker ALMR on April 17, 2026 |
About Alamar Biosciences
Alamar Biosciences specializes in ultrasensitive protein detection and quantification technologies for life sciences research and clinical applications. The company's flagship NULISA platform combines the specificity of immunoassays with the sensitivity and scalability of next-generation sequencing to detect thousands of proteins simultaneously from small sample volumes.
The company serves pharmaceutical companies, academic researchers, and clinical laboratories seeking to identify and validate protein biomarkers for drug development and diagnostic applications. Alamar's technology addresses critical needs in precision medicine by enabling more comprehensive protein analysis than traditional methods, potentially accelerating biomarker discovery and therapeutic development timelines.
IPO Status
Alamar Biosciences successfully completed its initial public offering on April 17, 2026, beginning trading on the Nasdaq under ticker symbol ALMR. The company priced its upsized IPO at $17 per share, the high end of its $15-$17 range, raising approximately $191 million. The offering was increased from the originally planned 9.375 million shares, reflecting strong investor demand for the proteomics company. The IPO proved highly successful, with shares opening at $22.60 and climbing approximately 40% on the first day of trading. The company celebrated the milestone by ringing the Nasdaq closing bell on its first trading day. The strong market debut represents a positive signal for the biotech sector and validates investor interest in Alamar's NULISA (Nucleic Acid-Linked Immuno-Sandwich Assay) technology platform for protein detection and biomarker discovery. The successful IPO positions Alamar to accelerate growth of its protein detection platform among researchers and pharmaceutical companies.
Competitors
Frequently Asked Questions
Does Alamar Biosciences have a stock?
No, Alamar Biosciences has not had an IPO yet and remains a private company. The company is currently focused on commercializing its protein detection technology platform.
When is the Alamar Biosciences IPO date?
Alamar Biosciences has not announced a specific IPO date, though market speculation suggests potential public market activity. No confirmed details about timing have been disclosed by the company. Sign up for alerts to stay informed.
How can I buy Alamar Biosciences stock?
Since Alamar Biosciences is still private, you cannot buy shares on public exchanges. If the company goes public, shares would become available through standard brokerage platforms. Sign up for alerts to stay informed.
Don't Miss the Next Big IPO
Get notified when the next major company files for an IPO. Daily alerts delivered to your inbox.
Get IPO Alerts